(Q44659388)

5 December 2017

title

Phospholipid and eicosanoid signaling disturbances in schizophrenia (English)

1 reference

5 December 2017

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14623494

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

3 April 2024

author name string

Brian M. Ross

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14623494

3 April 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14623494

3 April 2024

publication date

1 December 2003

1 reference

full work available at URL

5 December 2017

https://api.elsevier.com/content/article/PII:S0952327803001649?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

https://api.elsevier.com/content/article/PII:S0952327803001649?httpAccept=text/plain

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Prostaglandins, Leukotrienes and Essential Fatty Acids

3 April 2024

published in

1 reference

5 December 2017

volume

69

1 reference

5 December 2017

issue

6

1 reference

5 December 2017

page(s)

407-412

1 reference

Increased turnover of platelet phosphatidylinositol in schizophrenia

5 December 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Incorporation of 14C-arachidonic acid into platelet phospholipids of untreated patients with schizophreniform or schizophrenic disorders

3 April 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Degradation of specific polyunsaturated fatty acids in red blood cells stored at -20 degrees C proceeds faster in patients with schizophrenia when compared with healthy controls.

3 April 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases

3 April 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Membrane abnormalities in the psychoses and affective disorders

3 April 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Phospholipid patterns of erythrocytes in schizophrenia: relationships to symptomatology.

3 April 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Increased platelet membrane lysophosphatidylcholine in schizophrenia

3 April 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Effects of antipsychotic treatment on membrane phospholipid metabolism in schizophrenia

3 April 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy

3 April 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Frontal lobe metabolism and cerebral morphology in schizophrenia: 31P MRS and MRI studies

3 April 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy

3 April 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Study of chronic schizophrenics using 31P magnetic resonance chemical shift imaging

3 April 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

31P magnetic resonance spectroscopy of the medial temporal lobe of schizophrenic patients with neuroleptic-resistant marked positive symptoms

3 April 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy

3 April 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Elevated PLA2 activity in schizophrenics and other psychiatric patients

3 April 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Phospholipase A2 activity in serum of neuroleptic-naive psychiatric inpatients

3 April 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A2.

3 April 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Differential alteration of phospholipase A2 activities in brain of patients with schizophrenia.

3 April 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Phospholipase A2 activity is selectively decreased in the striatum of chronic cocaine users.

3 April 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Decreased activity of brain phospholipid metabolic enzymes in human users of cocaine and methamphetamine.

3 April 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Chronic cocaine administration reduces phospholipase A(2) activity in rat brain striatum

3 April 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Oxidative injury and potential use of antioxidants in schizophrenia

3 April 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Depression After Transient Ischemic Attack: A Clinically Distinct Subtype of Vascular Depression?

3 April 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Genetic variant near cytosolic phospholipase A2 associated with schizophrenia

3 April 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Association of the Ban I dimorphic site at the human cytosolic phospholipase A2 gene with schizophrenia

3 April 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Lack of association between schizophrenia and a polymorphism close to the cytosolic phospholipase A2 gene

3 April 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Red cell membrane fatty acids, cytosolic phospholipase-A2 and schizophrenia

3 April 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Association studies of cytosolic phospholipase A2 polymorphisms and schizophrenia among two independent family-based samples

3 April 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Lack of association between schizophrenia and the phospholipase-A(2) genes cPLA2 and sPLA2.

3 April 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia

3 April 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Phospholipase A2 activity in rat embryonic brain and in primary cultures of cortical neurons

3 April 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

The niacin challenge test: clinical manifestation of altered transmembrane signal transduction in schizophrenia?

3 April 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Tolerance to nicotinic acid flushing

3 April 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid

3 April 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans

3 April 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Niacin test in schizophrenia and affective illness

3 April 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

The niacin challenge test: clinical manifestation of altered transmembrane signal transduction in schizophrenia?

3 April 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Clinical subtyping reveals significant differences in calcium-dependent phospholipase A2 activity in schizophrenia

3 April 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Niacin-induced flush as a measure of prostaglandin activity in alcoholics and schizophrenics

3 April 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Niacin skin flush is not diagnostic of schizophrenia

3 April 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

Niacin skin flush in schizophrenia: a preliminary report

3 April 2024

52

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

A volumetric biochemical niacin flush-based index that noninvasively detects fatty acid deficiency in schizophrenia

3 April 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.012

3 April 2024

Identifiers

1 reference

5 December 2017

1 reference